Evidence suggests that bevacizumab (Avastin) can be effective in some cases of retinopathy of prematurity (ROP), specifically vision-threatening zone 1 ROP. In this 2011 Subspecialty Day presentation, Dr. Helen A. Mintz-Hittner discusses how to treat these select patients and the importance of vigilant follow-up. She also describes what is known about the toxicity of this drug in young infants, as well as the questions that future clinical trials must address.